Claims for Patent: 7,615,532

Summary for Patent: 7,615,532

Title:	Insulin derivatives
Abstract:	The present invention relates to insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the .alpha.-amino group of the N-terminal amino acid residue of the B chain or to the .epsilon.-amino group of a Lys residue present in the B chain of the parent insulin, the side chain being of the general formula: -W-X--Y-Z wherein W, X, Y and Z are as defined in the disclosure.
Inventor(s):	Jonassen; Ib (Valby, DK), Hoeg-Jensen; Thomas (Klampenborg, DK), Havelund; Svend (Bagsv.ae butted.rd, DK), Ribel-Madsen; Ulla (Virum, DK), Tagmose; Tina Moller (Ballerup, DK), Madsen; Peter (Bagsv.ae butted.rd, DK)
Assignee:	Novo Nordisk A/S (Bagsvaerd, DE)
Application Number:	11/343,005
Patent Claims:	1. An insulin derivative which is a naturally occurring insulin or an analogue thereof which has a side chain attached to the .alpha.-amino group of the N-terminal amino acid residue of the B chain or to the .epsilon.-amino group of a Lys residue present in the B chain of the parent insulin, the side chain being of the general formula: -W-X--Y-Z wherein W is: an .alpha.-amino acid residue having a carboxylic acid group in the side chain which amino acid is selected from the group consisting of .alpha.-Asp, .beta.-Asp, .alpha.-Glu, .gamma.-Glu, .alpha.-hGlu and .delta.-hGlu and which residue forms, with one of its carboxylic acid groups, an amide group together with the .alpha.-amino group of the N-terminal amino acid residue of the B chain or together with the .epsilon.-amino group of a Lys residue present in the B chain of the parent insulin; X is: --CO--; Y is: --(CH.sub.2).sub.m-- where m is an integer in the range of 6 to 32; Z is: --COOH; and any Zn.sup.2+ complexes thereof. 2. An insulin derivative according to claim 1, wherein side chain -W-X--Y-Z is attached to the .epsilon.-amino group of a Lys residue present in the B chain of the parent insulin. 3. An insulin derivative according to claim 1, wherein Y is --(CH.sub.2).sub.m-- where m is an integer in the range of from 12-16. 4. An insulin derivative according to claim 1, wherein the parent insulin is; des(B30) human insulin. 5. An insulin derivative according to claim 1, wherein the insulin derivative is N.sup..epsilon.B29--(N.sup..alpha.--(HOOC(CH.sub.2).sub.14CO)-.gamma.-Glu- ) des(B30) human insulin. 6. A zinc complex of an insulin derivative according to claim 1, wherein each insulin hexamer in said complex binds two zinc ions. 7. A zinc complex of an insulin derivative according to claim 1, wherein each insulin hexamer in said complex binds three zinc ions. 8. A zinc complex of an insulin derivative according to claim 1, wherein each insulin hexamer in said complex binds four zinc ions. 9. A pharmaceutical composition for the treatment of diabetes in a patient in need of such treatment, said composition comprising a therapeutically effective amount of an insulin derivative according to claim 1 together with a pharmaceutically acceptable carrier. 10. A pharmaceutical composition for the treatment of diabetes in a patient in need of such treatment, said composition comprising a therapeutically effective amount of an insulin derivative according to claim 1 in mixture with an insulin or an insulin analogue which has a rapid onset of action, together with a pharmaceutically acceptable carrier. 11. A pharmaceutical composition for the treatment of diabetes in a patient in need of such treatment, said composition comprising a therapeutically effective amount of an insulin derivative with a pharmaceutically acceptable carrier, wherein said insulin derivative is N.sup..epsilon.B29--(N.sup..alpha.--(HOOC(CH.sub.2).sub.14CO)-.gamma.-Glu- ) des(B30) human insulin. 12. A pharmaceutical composition for the treatment of diabetes in a patient in need of such treatment, said composition comprising a therapeutically effective amount of an insulin derivative in mixture with an insulin or an insulin analogue which has a rapid onset of action, together with a pharmaceutically acceptable carrier, wherein said insulin derivative is N.sup..epsilon.B29--(N.sup..alpha.--(HOOC(CH.sub.2).sub.14CO)--.gamma.-Gl- u) des(B30) human insulin.